PROTEBA
Biophysics + AI Platform
India’s first biophysics and Machine learning platform for early disease diagnostics — now available for licensing to clinicians, hospitals, healthcare providers and diagnostic laboratories. Translate cellular biology data into clinical-grade disease predictions at stage 0–1.
PROTEBA integrates early diagnostics and regenerative therapeutics to drive goldilocks balance of energy resistance.
A complete clinical solution — PROTEBA measures defects in mitochondrial energetics to drive non-invasive pre-clinical detection across metabolic diseases, IBD and oral cancer, and modulates dysregulated pathways using precision nutrition and regenerative therapeutics.
- Non-invasive metabolic diseases, gum disease, IBD & oral cancer screening from a single saliva sample
- Detection at the earliest, most treatable stages — stage 0–1 — before clinical symptoms appear
- L2 regression models trained on 35Bn+ molecular datasets — 70–80% sensitivity across disease models
- Clinical-grade computational biology platform for your practitioners — full pathway scoring and molecular insights
- Recurrent phenotype tracking for disease recurrence monitoring and long-term patient management
- Integration with existing lab work and DNA test insights for a comprehensive patient biological profile
- Biology-based dosages derived directly from each patient’s unique molecular pathway scores — true personalisation
- Regenerative therapeutics that reinstate ion channels and gap junctions to drive diverse cellular intelligence
- Mitochondrial remodelling — using nutrition and regenerative therapeutics to reinstate stable cell voltage (–90mV) and anatomical homeostasis
- W³ approach: food that nourishes with biology-based dosages, foods to avoid, and signalling molecules to modulate dysregulated pathways
- Red Flag Model — real-time tracking of how daily nutrition choices impact dysregulated pathways and symptomatic conditions
- 360-degree feedback loop: monthly intervention revisions based on phenotype improvements, correlated with lab work
Mitochondrial Energy Resistance — the universal biomarker for disease onset.
PROTEBA applies physics on human biological systems to identify breakdown in the energetic processes of mitochondria at an early stage and reinstate goldilocks balance of energy resistance using regenerative therapeutics that drives tissue remodelling and anatomical homeostasis.
Mitochondrial Energy Resistance (MER) is the master biomarker. Elevated MER — driven by gut & oral microbial dysbiosis, environmental toxins, systemic inflammation and oxidative stress — is the molecular precursor to every metabolic disease PROTEBA detects.
- Environmental & internal toxins
- Gut & oral microbial dysbiosis
- Hormonal Imbalances
- Systemic Inflammation
- Oxidative Stress
- Nutrient absorption
- Oral Hygiene
- NADH to NAD⁺ ratio
- Lactate : Pyruvate, Alanine
- Cytokines : cell derived
- Oxidative damage
- Detoxification pathways
- Dissipative heat
- Telomere Length
From 10 million molecules to a clinical-grade disease prediction at stage 0–1.
High accuracy & precision across five disease models.
PROTEBA’s models are trained on the largest proprietary molecular dataset in India — 35Bn cellular data points, 30Mn cellular features and 40Mn phenotype data points, cross-referenced with 35,000 clinical studies.
80% improvement in disease phenotype over 3 years.
Genefitletics customers reported measurable improvement in disease phenotype across all tracked conditions over a 3-year longitudinal period. PROTEBA licensing partners gain access to this documented outcomes data — with remission timelines per condition.
The true personalisation — biology-based precision nutrition.
PROTEBA’s therapeutics layer is the clinical intervention engine. It takes the Cellular Footprint — molecular insights, cellular insights, mitochondrial signalling pathways, nutrient absorption, and predicted insulin response — and generates individualised nutrition and biotherapeutics protocols for your patients.
A unique winning proposition for your clinical practice.
PROTEBA licensing gives clinicians, hospitals and diagnostic labs a first-mover advantage in India’s early diagnostics space — with a differentiated offering that blends microbiome sequencing, mitochondrial testing and cellular biomarkers into your existing clinical workflows.
Give your patients control of their cells.
Join India’s most advanced biophysics + system biology clinical platform. PROTEBA licensing is available for individual clinicians, multi-specialty hospitals, diagnostic labs and preventive healthcare chains.
Request Partnership →